Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Core Viewpoint - Allarity Therapeutics has successfully closed a $20 million non-convertible debt financing to support the development of stenoparib, a dual PARP and WNT pathway inhibitor, aimed at advancing its clinical trials and commercialization efforts [1][3][4] Financing Details - The financing consists of two non-convertible promissory notes: one for $10,930,000 and another secured note for $10,000,000, totaling approximately $20 million in net proceeds [2] - This financing is expected to extend the company's cash runway into the summer of 2028 [3][6] Use of Proceeds - The funds will primarily be used to support key initiatives for stenoparib, including completing Phase 2 enrollment, preparing for an FDA meeting, and advancing the companion diagnostic strategy [3][4] - The financing also supports broader strategic initiatives, including the development of the DRP companion diagnostic platform and exploratory development in additional WNT-driven tumor types [4] Clinical Development - Stenoparib has shown durable clinical benefits in heavily pre-treated ovarian cancer patients, with some patients remaining on therapy for over 30 months [4] - The ongoing open-label Phase 2 trial aims to generate critical clinical data to inform future regulatory engagement and pivotal trial development [4][5] About Stenoparib - Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2, with potential applications in various cancer types, including ovarian cancer, small cell lung cancer, and colorectal cancer [5] - Allarity holds exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. [5][9] About Allarity Therapeutics - Allarity Therapeutics is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments, particularly stenoparib, using its DRP® technology to identify patients likely to benefit from the drug [9]